Macugen works by blocking vascular endothelial growth factor (VEGF), a protein that promotes blood vessel growth. Macugen has the potential for helping all patients with the wet form of macular degeneration. The results of the current clinical trial did indicate that Macugen can slow vision loss, but it did not appear to significantly improve vision, contrary to the results of some earlier smaller studies.